CDX
A-375
Tumor indication
Melanoma
Tumor subtype
Malignant Melanoma
Description
A-375 (Melanoma CDX Model)
The A-375 melanoma cell line was established from a female patient with malignant melanoma. It carries the BRAF V600E mutation, a key driver of melanoma progression. This mutation makes A-375 one of the most widely used preclinical models for targeted therapy studies. Its defined genetics provide a strong foundation for precision oncology research.
Key Features:
- Derived from malignant melanoma of the skin.
- Contains BRAF V600E mutation.
- Strong MAPK pathway activation.
- Well suited to targeted therapy studies.
Applications:
A-375 is applied in studies of BRAF and MEK inhibitor response. It is also used in immuno-oncology and combination therapy evaluation. Researchers employ this model to investigate MAPK pathway biology and drug resistance. Its reproducibility makes it a benchmark system in melanoma research.
Details
- Tumor indication
- Melanoma
- Tumor subtype
- Malignant Melanoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.